Market
Rights offering to existing shareholders followed by a public offering of unsubscribed shares Full amount of planned issuance paid in
HLB Pharmaceutical has completed payment for its rights offering to existing shareholders. The offering totaled 60.8 billion won.
HLB Pharmaceutical disclosed on the 18th through the Electronic Disclosure System (DART) that payment had been completed for a rights offering of 10,762,332 common shares at 5,650 won per share. The total offering amount was 60,807,175,800 won.
The offering was conducted through a rights offering to existing shareholders followed by a public offering of unsubscribed shares. The planned and actual number of shares issued was the same: 10,762,332.
The company approved the rights offering at a board meeting on May 13. With the payment, the full planned amount of the issuance was subscribed.
The new shares are scheduled to be listed on Oct. 7.
Biobook Team
biobookmedia@biobook.co.kr
Orient Bio Expands Domestic Supply of SPF Rabbits, but Reversal of Chronic Losses Remains Elusive
Celltrion’s Third-Quarter Operating Profit Surges 69% to 510 Billion Won
ViOL Medical Wins Thai Approval for HIFU Device, Laying Groundwork for Consumables Revenue
SCD Pharm’s glaucoma drug Latast reaches 11% market share, supplied back to originator
Alteogen’s ALT-B4 Infringes Halozyme Patent in Europe; Keytruda SC Sales Banned in 8 Countries
Immunology Drug Developer TrexBio Prices $117 Million IPO
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
